BC-PIV SARS-CoV-2 vaccine / MediciNova, BioComo - LARVOL DELTA

MediciNova Announces Update on SARS-CoV-2 Vaccine for COVID-19 (GlobeNewswire) - "MediciNova has conducted a careful review of its numerous development programs...Given the COVID-19 vaccines currently in use and other vaccines in advanced stages of development, MediciNova has decided to discontinue development of a SARS-CoV-2 vaccine for COVID-19 in order to maintain adequate resources for its other development programs which have indications with larger unmet medical needs and market opportunities."

Discontinued • Infectious Disease • Novel Coronavirus Disease

MediciNova Announces SARS-CoV-2 Vaccine Joint Development with BioComo and Mie University Japan (GlobeNewswire) - "MediciNova, Inc....today announced an agreement with BioComo...and Mie University (Mie prefecture, Japan) for joint development of a SARS-CoV-2 vaccine using BC-PIV....MediciNova has been granted exclusive worldwide development rights to use BC-PIV for SARS-CoV-2 vaccine development from BioComo and Mie University....'We will proceed with further non-clinical and clinical trial development...'"

Licensing / partnership • Infectious Disease • Novel Coronavirus Disease